|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
National Institute of Allergy and Infectious Diseases (NIAID) |
| Information provided by: | National Institute of Allergy and Infectious Diseases (NIAID) |
| ClinicalTrials.gov Identifier: | NCT00000832 |
Purpose
To determine the safety and immunogenicity of rgp120/HIV-1SF2 combined with MF59 adjuvant emulsion versus MF59 alone in HIV-negative volunteers.
One approach to improve the immunogenicity of an HIV-1 subunit protein vaccine is to combine the immunogen with an adjuvant.
| Condition | Intervention | Phase |
|
HIV Infections |
Biological: MF59 Biological: rgp120/HIV-1 SF-2 |
Phase I |
| MedlinePlus related topics: | AIDS |
| Study Type: | Interventional |
| Study Design: | Prevention, Double-Blind, Safety Study |
| Official Title: | A Randomized, Placebo-Controlled, Double-Blinded Phase I Safety and Immunogenicity Trial of Recombinant Envelope Protein, HIV-1 SF-2 rgp120 (BIOCINE), Combined With MF59 in HIV-1 Uninfected Adult Volunteers |
| Estimated Enrollment: | 30 |
One approach to improve the immunogenicity of an HIV-1 subunit protein vaccine is to combine the immunogen with an adjuvant.
Healthy volunteers receive intramuscular injections of rgp120/HIV-1SF2 with MF59 adjuvant emulsion or MF59 alone at months 0, 1, 6, 9, 10 and 12 (was months 0, 1, 6 and 10, amended 12/19/96).
Eligibility
| Ages Eligible for Study: | 18 Years to 60 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria
Volunteers must have:
Exclusion Criteria
Co-existing Condition:
Subjects with the following symptoms or conditions are excluded:
Subjects with the following prior conditions are excluded:
Prior Medication:
Excluded:
Prior Treatment:
Excluded:
Identifiable high-risk behavior for HIV infection, including:
Contacts and Locations| United States, Alabama | |||||
| Univ of Alabama at Birmingham | |||||
| Birmingham, Alabama, United States, 35294 | |||||
| United States, Maryland | |||||
| Johns Hopkins Univ / School of Hygiene & Public Health | |||||
| Baltimore, Maryland, United States, 212051901 | |||||
| United States, Missouri | |||||
| St Louis Univ School of Medicine | |||||
| St. Louis, Missouri, United States, 63104 | |||||
| United States, New York | |||||
| Univ of Rochester Med Ctr | |||||
| Rochester, New York, United States, 14642 | |||||
| United States, Tennessee | |||||
| Vanderbilt Univ Hosp | |||||
| Nashville, Tennessee, United States, 37232 | |||||
| United States, Washington | |||||
| Univ of Washington / Pacific Med Ctr | |||||
| Seattle, Washington, United States, 98144 | |||||
| Study Chair: | Corey L |
More Information
|
Corey L, Weinhold K, Montefiori D, Stablein D. CTL and neutralizing antibody responses with a combination HIV-1 vaccine regimen. Int Conf AIDS. 1998;12:636 (abstract no 33221)
  |
|
Kahn JO, Sinangil F, Baenziger J, Murcar N, Wynne D, Coleman RL, Steimer KS, Dekker CL, Chernoff D. Clinical and immunologic responses to human immunodeficiency virus (HIV) type 1SF2 gp120 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidylethanolamine in non-HIV-infected human volunteers. J Infect Dis. 1994 Nov;170(5):1288-91.
  |
| Study ID Numbers: | AVEG 024 |
| First Received: | November 2, 1999 |
| Last Updated: | June 23, 2005 |
| ClinicalTrials.gov Identifier: | NCT00000832 |
| Health Authority: | United States: Federal Government |
|
|
|
|
|